The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharma ceutically acceptable excipient. The present disclosure fur ther provides a method for treating MPE by using the pharmaceutical composition.
The present disclosure relates to a method for treating malignant pleural effusions (MPE) in a subject, particularly for treating MPE in a subject suffering from lung cancer, breast cancer, lymphoma, leukemia, or mesothelioma in a late stage by a novel pharmaceutical composition compris ing benzenesulfonamides. The present disclosure also relates to a pharmaceutical composition comprising benze nesulfonamides and a process for preparation thereof.
2. Description of Related Art Cancers with various origins have been serious diseases worldwide. The later stage of cancer is diagnosed, the lower cure rate is. Malignant pleural effusions (MPE) resulted from metastatic malignant pleural tumors or primary malig nant pleural tumors is one of the most common complication of malignant tumors. It is reported that 24% to 50% of exudative pleural effusions originated from malignant lesions and 50% of tumor metastasis finally lead to MPE. Top three MPE generating cancers are lung cancer the first, breast cancer the second, and lymphoma the third. The primary cancer tumor lesions have not been found in about 5% to 10% of MPE cases. All malignant tumors excluding primary brain tumor and limbs tumor may generate MPE (Am J Respir Crit Care Med Vol. 162. P. 1987-2001, 2000) .
MPE is often regarded as a complication in the late stage of tumors. MPE is rapidly developing and often complicated with the symptoms such as chest tightness, shortness of breath, palpitations, and unable Supine. Delaying the treat ment of MPE might cause barriers of respiration and circu lation, hypoproteinemia, and anemia, and the severe symp toms might be life-threatening. Therefore, rapidly and effectively treating MPE is an important step in cancer therapy. However, the treatment of MPE is difficult due to high mortality rate. The one, three and six-month(s) mor tality rates of patients with MPE are 50%, 60%, and 82%, respectively. The average life expectancy is merely 3.1 months. Effectively managing MPE has been one of the difficult issues in clinical treatments.
In clinical practice, removing pleural effusions and pre venting its accumulation again, relieving symptoms, raising life quality, as well as extending Survival period are the current main treatments for MPE. The major methods include chest drainage, video-assisted thoracic Surgery (VATS), intrathoracic administration, pleural fixation, whole body chemotherapy, radiotherapy, thermal therapy and the like. However, limitation exists in each treatment applica tion which results in limited therapy efficacy. Recently hyperthermic pleural perfusion treatment provides a new method and it is theoretically and technically supported. There are two kinds of hyperthermic pleural perfusion treatments: one is physiological saline, which exhibits low timeliness to pleural effusions control and high recurrence; the other is chemotherapy by cisplatin and so on, which is used for local anti-cancer and promoting pleural connection. However, over pleural connections are frequently observed in clinical practice, resulting in fibrin depositing on pleura, pleural capillaries and fibroblasts extending into fibrin and forming granulation tissue, gradually thickening to dense envelope and forming pleural fibreboard. The wide and rigid fibreboard wraps around the lung tissue and lacks flexibility, So as to limit chest expansion, severely reduce breath and increase the recurrence rate of pleural effusions. As a result, a pleural perfusion liquid effectively improving function of respiratory system and reducing recurrence rate remains a need yet to be met.
MPE is a secondary symptom of primary tumor. There fore, the attention of clinical study and the improvement of treatment are relatively limited compared to other main stream domains of tumor study. Meanwhile, the commercial profit is also limited. In view of the above problem of the conventional art, the technical purpose of the present dis closure is to provide a new medication with assured effect and fewer side effects to treat MPE. The study on MPE by benzenesulfonamides is so far underreported.
Chinese There are certain methods in treating MPE by Chinese medicine based on five compound medications described above, but their clinical evidences of treating MPE are not sufficient yet. As such, the efficient results of the clinical 3 treatment are hardly achieved due to the defect of five patented medications described above.
SUMMARY OF THE INVENTION
In one aspect of the present disclosure, a pharmaceutical composition for treating malignant pleural effusions (MPE) is provided. The pharmaceutical composition comprises a benzenesulfonamide derivative and a pharmaceutically acceptable excipient.
In one embodiment of the present disclosure, the benze nesulfonamide derivative may be a compound represented by formula (I):
wherein R-R are each independently selected from the group consisting of H. C1-C6 linear or branched alkyl, C1-C6 linear or branched alkoxy, amino, halo, halo-substi tuted C1-C6 linear or branched alkyl, and sulfonamide group.
In one embodiment of the present disclosure, the com pound of formula (I) may be selected from the group consisting of p-toluenesulfonamide or o-toluenesulfona mide, N-ethyl-p-toluene sulfonamide, N-ethyl-o-toluene Sulfonamide, N-cyclohexyl-p-toluene Sulfonamide and a combination thereof.
In one embodiment of the present disclosure, the benze nesulfonamide derivative may be present in an amount ranging about 10%-50% by weight. In one embodiment of the present application, the pharmaceutical composition may comprise 10%-50% by weight of the benzenesulfonamide derivative, 10%-40% by weight of PEG-400, 5%-10% by weight of 1,2-propylene glycol, 1%-5% by weight of sebacic acid, 10%-20% by weight of 2-ethyl-1,3-hexanediol, 0%-10% by weight of dimethyl sulfoxide and 0%-10% by weight of ethanol.
In another aspect of the present disclosure, the method for treating malignant pleural effusions is provided. The method comprises administering a therapeutically effective amount of the pharmaceutical composition comprising a benzene sulfonamide derivative to a subject in need thereof.
In one embodiment of the present disclosure, the phar maceutical composition may be administered to the Subject intratumorally, intravenously, Subcutaneously, intrader mally, orally, intrathecally, intraperitoneally, intranasally, intramuscularly, intrapleurally, or through nebulization. In another embodiment of the present disclosure, the pharma ceutical composition is administered intrapleurally to the Subject.
In one embodiment of the present disclosure, the subject may be suffering from cancer, such as lung cancer, breast cancer, lymphoma, leukemia, and mesothelioma.
In one embodiment of the present disclosure, the method further comprises administering at least one additional MPE therapy to the subject. The additional MPE therapy may be selected from chest drainage, video-assisted thoracic Surgery The following examples are used to exemplify the present disclosure. A person of ordinary skills in the art can under stand the other advantages of the present disclosure, based on the disclosure of the specification of the present disclo Sure. The present disclosure can also be implemented or applied as described in different specific examples. It is possible to modify and or alter the examples for carrying out this disclosure without contravening its spirit and scope, for different aspects and applications.
It is further noted that, as used in this specification, the singular forms "a," "an, and "the include plural referents unless expressly and unequivocally limited to one referent. The term 'or' is used interchangeably with the term "and/ or unless the context clearly indicates otherwise.
The present disclosure provides a pharmaceutical com position comprising a therapeutically effective amount of benzenesulfonamides as a medicament for MPE and also provides a process for preparing the above composition and a treatment method using the composition. The pharmaceutically acceptable excipient included in the pharmaceutical composition of the present disclosure may be conventional pharmaceutical carriers, such as filler, binder, preservative, disintegrating agent, lubricant, Sus pending agent, wetting agent, solvent, Surfactant, acids and flavoring agent.
The binders that are suitable for use in the present disclosure may be starch paste, Sorbitol, guar gum, polyvinyl pyrrolidone, cellulose derivatives such as hydroxy propyl methyl cellulose, sodium carboxymethyl cellulose, car bomer (commercially available as carbopols) etc.
The preservatives suitable for use in the present disclosure may be sodium benzoate, methyl paraben, propyl paraben, The flavoring agents that are Suitable for use in the present disclosure may be peppermint oil, menthol, lemon oil, orange oil, and cinnamon oil.
Preferably, the pharmaceutically acceptable excipient may be polyethylene glycol (PEG), alkylene glycol, Sebacic acid, and/or dimethyl sulfoxide, alcohols. More preferably, the pharmaceutical compositions may comprise the follow ing parts by weight: The present disclosure also provides the process for the preparation of pharmaceutical composition.
The process includes: adding and mixing the solvents and adjuvants in a given ratio; heating the mixture to 80° C. to 110° C. with stirring to form a clear oily liquid; gradually adding the Sulfa drug with stirring until completely dis Solved; filtering and cooling the mixture to obtain the composition of the present disclosure in an oily liquid form (GNW-601).
The process for preparing the injection formulation of GNW-601 may be carried out based on the technique known in the art, for example, by adding adjuvants or and solvents, and further adjusting the mixture to isotonic condition. For example, microporous filters can be used for the step of filtering in the process.
The pharmaceutical composition of benzenesulfonamides may be formulated into a form suitable for parenteral administration, injection, continuous infusion, Sublingual administration, Subcutaneous administration or oral admin istration. In one embodiment of the present disclosure, the pharmaceutical composition may be in a form selected from the group consisting of a formulated to injection, dry pow ders, tablets, oral liquid, wafers, films, lozenges, capsules, granule, and pill.
For example, GNW-601 for treating MPE can be a Solution form and administered to a subject by intramuscular or intrapleural injection or by oral or other routes. GNW-601 also can be other formulation for the oral administration as a medicament for treating MPE. The intrapleural injection dosage for MPE treatment is 3-8 mL/injection (about 990 2640 mg), twice per week with 4-week period as a course.
The injection dosage for adults is 1000 mg-1800 mg of p-toluenesulfonamide or other benzenesulfonamides. The oral dosage is 150-1800 mg of p-toluenesulfonamide or other benzenesulfonamides per day.
The present disclosure provides the use of GNW-601 as a medicament for treating MPE. By the long-term clinical trials, it is proven that the pharmaceutical composition of the present disclosure can improve the clinical symptoms and the life quality of MPE patients. The pharmaceutical composition of the present disclosure is preferably a targeted prescription with the efficacy to the best performance compared to current avail able medications for treating MPE. Total 46 cases with MPE were enrolled, there were 16 male and 30 female, aged from 19 to 83 years, and their average age was 54.80+11.62 years. There were 22 cases of squamous cell carcinoma, 18 cases of lung adenocarcinoma, 3 cases of pleural metastasis in breast cancer, and 3 cases of pleural metastasis from primary liver cancer based on his tology examination.
Diagnostic criteria: A. patients with advanced cancer, breathing difficulties, chest tightness, and flatness by aus cultation, B. chest radiography, B ultrasound, CT scan confirmed MPE, C. pleural effusion, histopathological or cytological examination revealed malignant cells, D. pleural effusion with CEA value >10-12 ng/mL, E. exclusion of other causes of pleural effusion.
Inclusion criteria: A. at least one imaging (CT, X ray, or B ultrasound) showing the quantity of MPE within 2 weeks from enrollment, B. confirmed MPE by histological or cytological diagnosis, C. normal functions of liver, kidney, and blood, D. Karnofsky score -50, expected survival time >3 months, E. no interstitial pneumonia or pulmonary fibro sis, F. excluding diagnostic puncture, no treatment of che motherapy and intrapleural medication injection within one month before enrollment, G. informed consent forms signed by patients or their family members.
Exclusion criteria: A. end-stage patients with cachexia and severe hypoalbuminemia; Karnofsky score 250, unable to complete one course of treatment, B. basal treatment combined with other anti-cancer therapies, C. other causes of pleural effusions such as infections and cardiopathy, D. pregnant women, or mental disorders, or those not following the treatment scheme.
Meeting at least one of the following criteria should be withdrawn from the clinical trial: A. rapidly deterioration or death during trial, B. patient condition or patient himself requesting stop of treatment before completion of a course, C. those poorly complying with scale fill, D. not meeting inclusion criteria after enrollment.
Treatment methods: before GNW-601 administration, remove MPE was performed with the intrathoracic injection needle one or two times (800-1400 mL per day) when necessary. GNW-601 was intrathoracically injected 3-8 mL (about 990-2,640 mg), two times per week with 4-week as one course. On average, patients were conducted for four times of treatment.
Response Evaluation Criteria: Evaluation criteria of remission of pleural effusion were based on term effect in accordance with the provisions of WHO standards. Complete remission (CR): pleural effusion completely disappeared and maintained for at least 4 weeks; partial remission (PR): pleural effusion significantly reduced (>50% reduction) and maintained for 4 weeks; stable (SD): 7 pleural effusion decreased without increasing trend; prog ress (PD): no reduction or increase in pleural effusion. The total efficacy: CR+PR.
Evaluation criteria of life quality were according to WHO universal Karnofsky performance status Scale. The improve ment was defined as 10 or more points increase after treatment and the reduction was defined as 10 or more points decrease after treatment. Those increase or decrease less than 10 points were defined as stable. Clinical benefit rate: improvement+stable.
Clinical evaluation and scoring criteria included guiding patients to fill in case report forms based on the severity of symptoms (dyspnea, cough, chest pain, weight loss, cough ing up blood and sputum, lassitude, loss of appetite, etc.), grading from 0 to 6 points as a counterpart symptom score (the higher the score, the more severe the symptoms), and recording and comparing the score difference before and after treatment for each patient in the group to confirm the efficacy of treatments (the greater the score difference, the greater the improvement).
Adverse reactions were reported according to the grading standards of common adverse reactions in clinical trials issued by WHO in 1989, focusing on observation of nausea, Vomiting, diarrhea and other gastrointestinal reactions, as well as leukopenia and bone marrow Suppression.
Observation Methods:
Outcome measures included: A. general recording items, B. relieved conditions of pleural effusion, C. the changes in the life quality, D. the changes in clinical grading scores, E. adverse reactions including gastrointestinal reactions, bone marrow Suppression, effects on the functions of liver and kidney.
Observation time points: recording the general items upon enrollment (e.g., name, gender, age, duration of disease, primary tumor pathology, and pleural effusion and its posi tion, syndromes and Karnofsky score), weekly measuring blood and blood biochemistry for four weeks, filling case reports one day before treatment and seven days after the treatment, and determining the actual MPE relieved condi tion one month after treatment. The reduction of MPE was verified by X ray or B ultrasound. wherein the at least one additional MPE therapy is chest drainage. 2. The method according to claim 1, wherein the benze nesulfonamide derivative in the pharmaceutical composition is administered to the subject in a therapeutically effective amount of from about 1000 mg to about 1800 mg per day.
3. The method according to claim 1, wherein the phar maceutical composition is administered to the subject intra tumorally, intravenously, Subcutaneously, intradermally, orally, intrathecally, intraperitoneally, intranasally, intramus cularly, intrapleurally, or through nebulization.
4. The method according to claim 1, wherein the subject is suffering from cancer.
5. The method according to claim 4, wherein the cancer is at least one selected from the group consisting of lung cancer, breast cancer, lymphoma, leukemia, and mesothe lioma.
6. The method according to claim 1, wherein the addi tional MPE therapy is further consists of video-assisted thoracic Surgery (VATS), intrathoracic administration, pleu ral fixation, whole body chemotherapy, radiotherapy, or thermal therapy.
7. The method according to claim 1, wherein the com pound of formula (I) is selected from the group consisting of p-toluenesulfonamide, o-toluenesulfonamide, N-ethyl-ptoluene sulfonamide, N-ethyl-o-toluene sulfonamide, N-cy clohexyl-p-toluene Sulfonamide and a combination thereof.
8. The method according to claim 1, wherein the benze nesulfonamide derivative is present in the pharmaceutical composition in an amount ranging from about 10% to about 50% by weight.
9. The method according to claim 8, wherein the phar maceutical composition further comprises at least one of 10%-40% by weight of PEG-400, 5%40% by weight of 1,2-propylene glycol, 1%-5% by weight of sebacic acid, 10%-20% by weight of 2-ethyl-1,3-hexanediol, 0%-10% by weight of dimethyl sulfoxide and 0%-10% by weight of ethanol.
